HYFT — MindWalk Holdings Corp.

Summary of HYFT Earnings Call (Q4 2026)

1. Key Financial Results and Metrics

• Revenue Growth: Total revenue for fiscal 2026 reached CAD 15.6 million, a 46% increase from CAD 10.6 million in the previous year. Q4 2026 revenue was CAD 4.1 million, up 50% from CAD 2.7 million in Q4 2025.
• Gross Margin: Expanded to 59% for the year (CAD 9.1 million) from 54% in the prior year, with Q4 gross margin at 61%.
• Net Loss: Net loss from continuing operations was CAD 15.1 million, significantly reduced from CAD 33.1 million in the previous year. Q4 net loss was CAD 3.9 million, compared to CAD 3.4 million in Q4 2025.
• Cash Position: Ended fiscal 2026 with CAD 11.5 million in cash, slightly up from CAD 10.8 million a year earlier.

2. Strategic Updates and Business Highlights

• Platform Development: Successful integration of the discovery engine and bio-native AI into a unified platform, leading to the launch of ReefIQ and the signing of the first two recurring revenue contracts.
• Client Engagement: Over 20 molecules have been put into clinical trials, with one achieving FDA approval and commercial launch.
• Market Positioning: Regained NASDAQ compliance and inclusion in the Russell 3000E and Russell Microcap Indexes, enhancing institutional visibility.
• Partnerships: Collaboration with AMD to optimize the AI platform, demonstrating significant performance improvements in operational efficiency.

3. Forward Guidance and Outlook

• Revenue Model Transition: Focus on building intelligence-driven recurring revenue through deeper client engagements with LensAI and ReefIQ.
• Investment in Growth: Anticipated increase in operating expenses as the company invests in pipeline assets and commercial infrastructure.
• Pipeline Development: Continued focus on advancing proprietary biologics and vaccine programs, including dengue, influenza, and GLP-1, with potential for nondilutive funding.

4. Bad News, Challenges, or Points of Concern

• Recurring Revenue Contribution: The contribution from the newly signed recurring revenue contracts is still modest and not yet material to overall revenue.
• Net Losses: Despite narrowing losses, the company continues to operate at a significant net loss, raising concerns about long-term sustainability without further revenue growth.
• Market Competition: The AI drug discovery sector remains competitive, with ongoing risks related to intellectual property and market acceptance of new technologies.

5. Notable Q&A Insights

• Recurring Revenue Clarification: Management indicated that while the new SaaS contracts are not yet significant in revenue terms, they are seen as a crucial step towards establishing a recurring revenue model.
• Operating Expenses: Expected to increase as investments in R&D and commercial initiatives continue, although management aims to maintain tight control over capital allocation.
• Pipeline Updates: No immediate updates on clinical data or IND-enabling studies, with a focus on ensuring that any disclosures do not jeopardize IP protection. Management emphasized the importance of material updates over incremental progress reports.

Overall, MindWalk Holdings Corp. demonstrated significant growth in revenue and gross margins while narrowing losses, but faces challenges in scaling its recurring revenue model and managing operational expenses. The strategic focus on partnerships and proprietary technology development positions the company for future growth, albeit with inherent risks in a competitive landscape.